Shire is paying $20 million up front to acquire rights to a drug that Parion Sciences has developed as a potential treatment for dry eye disease. The deal calls for Shire (NASDAQ: SHPG) to take the lead on further work on P-321, a compound that Durham, NC-based Parion has tested in early-stage clinical trials. If […]
What Our Clients Say
[ssba_hide]
[testimonials category="Testimonial" random=true limit="1"]
Press Releases and Whitepapers
Industry News & Articles
- Google Maps can now build trip itineraries with real-time details about each stop
- Mazama Energy has a solution for geothermal’s biggest drilling problem
- After dodging death, battery startup Our Next Energy is now going public
- Bedrock Energy raises $24M to build more AI-enabled geothermal drill rigs for enterprise buildings
- Freshworks alums raise $53M to take on Salesforce, HubSpot with AI-native CRM
- Zoox robotaxis are now on the Uber app in Las Vegas
- Helsing backer Plural raises $1.1B to fund Europe’s next moonshots
- Apple launches new app to study how people use AI for health
Sample Relationships
[logo-carousel id=relationships]
Notables
[logo-carousel id=notables]